KR100969856B1 - 간암을 진단하기 위한 마커인 mgp, 그를 포함하는 키트및 상기 마커를 이용한 간암 예측 방법 - Google Patents
간암을 진단하기 위한 마커인 mgp, 그를 포함하는 키트및 상기 마커를 이용한 간암 예측 방법 Download PDFInfo
- Publication number
- KR100969856B1 KR100969856B1 KR1020080006208A KR20080006208A KR100969856B1 KR 100969856 B1 KR100969856 B1 KR 100969856B1 KR 1020080006208 A KR1020080006208 A KR 1020080006208A KR 20080006208 A KR20080006208 A KR 20080006208A KR 100969856 B1 KR100969856 B1 KR 100969856B1
- Authority
- KR
- South Korea
- Prior art keywords
- liver cancer
- mgp
- marker
- protein
- genes
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (8)
- 서열번호 1의 MGP (matrix Gla protein) 단백질에 특이적으로 결합하는 항체, 또는 상기 단백질을 코딩하는 유전자에 특이적으로 결합하는 프라이머 또는 프로브를 포함하는, 간암을 진단하기 위한 마커 검출용 조성물.
- 삭제
- 삭제
- 삭제
- 제1항의 조성물을 포함하는, 간암을 진단하기 위한 마커 검출용 키트.
- MGP (Matrix Gla protein)를 포함하는, 간암을 진단하기 위한 마이크로어레 이.
- 간암 진단에 필요한 정보를 제공하기 위하여 환자의 시료로부터 MGP (Matrix Gla protein)의 발현 수준을 정상 세포의 발현 수준과 비교하여 간암 마커 MGP (Matrix Gla protein)를 검출하는 방법.
- 간암 절제 수술의 예후 예측에 필요한 정보를 제공하기 위하여 간암 절제 수술을 받은 환자의 시료로부터 MGP (Matrix Gla protein)의 발현 수준을 정상 세포의 발현 수준과 비교하여 간암 마커 MGP (Matrix Gla protein)를 검출하는 방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080006208A KR100969856B1 (ko) | 2008-01-21 | 2008-01-21 | 간암을 진단하기 위한 마커인 mgp, 그를 포함하는 키트및 상기 마커를 이용한 간암 예측 방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080006208A KR100969856B1 (ko) | 2008-01-21 | 2008-01-21 | 간암을 진단하기 위한 마커인 mgp, 그를 포함하는 키트및 상기 마커를 이용한 간암 예측 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090080316A KR20090080316A (ko) | 2009-07-24 |
KR100969856B1 true KR100969856B1 (ko) | 2010-07-13 |
Family
ID=41291432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080006208A KR100969856B1 (ko) | 2008-01-21 | 2008-01-21 | 간암을 진단하기 위한 마커인 mgp, 그를 포함하는 키트및 상기 마커를 이용한 간암 예측 방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100969856B1 (ko) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010044414A1 (en) * | 1999-12-10 | 2001-11-22 | Whitehead Institute For Biomedical Research | Metastasis genes and uses thereof |
-
2008
- 2008-01-21 KR KR1020080006208A patent/KR100969856B1/ko active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010044414A1 (en) * | 1999-12-10 | 2001-11-22 | Whitehead Institute For Biomedical Research | Metastasis genes and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20090080316A (ko) | 2009-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180106817A1 (en) | Protein biomarkers and therapeutic targets for renal disorders | |
EP2430193B1 (en) | Markers for detection of gastric cancer | |
CN107326066B (zh) | 用于膀胱癌检测的尿标记物 | |
DK2638398T3 (en) | Hitherto UNKNOWN MARKET FOR THE DETECTION OF BLADE CANCER AND / OR INFLAMMATORY CONDITIONS IN THE BLADE. | |
WO2002009573A2 (en) | Prognostic classification of endometrial cancer | |
KR101478826B1 (ko) | 신규한 대장암 진단용 마커 및 이를 이용한 대장암 진단 키트 | |
KR20130017525A (ko) | 대장암, 유방암, 신장암 또는 갑상선암의 조기 진단을 위한 바이오 마커 및 이의 용도 | |
KR101054952B1 (ko) | 간암 진단 및 환자 생존기간 예측용 마커인 uqcrh, 그를 포함하는 키트 및 상기 마커를 이용한 간암 환자 생존기간 예측 | |
JP2007263896A (ja) | 肺癌患者の術後予後予測のための生物マーカー及びその方法 | |
KR101657051B1 (ko) | 만성폐쇄성폐질환 진단용 마커 조성물 | |
KR100969856B1 (ko) | 간암을 진단하기 위한 마커인 mgp, 그를 포함하는 키트및 상기 마커를 이용한 간암 예측 방법 | |
KR101054953B1 (ko) | 간암을 진단 및 치료하기 위한 분자인 snx14, 그를 포함하는 키트 | |
KR101006226B1 (ko) | 간암을 진단하기 위한 마커인 cxcl2, 그를 포함하는키트 및 상기 마커를 이용한 간암 예측 방법 | |
KR100768943B1 (ko) | 자궁암을 진단하기 위한 마커인 sybl1과 tm9sf1,이들을 포함하는 키트 및 상기 마커를 이용한 자궁암 예측방법 | |
KR20090080318A (ko) | 간암을 진단하기 위한 마커인 ggh, 그를 포함하는 키트및 상기 마커를 이용한 간암 예측 방법 | |
US20150011411A1 (en) | Biomarkers of cancer | |
KR101054951B1 (ko) | 간암을 진단 및 치료하기 위한 분자인 capn12, 그를 포함하는 키트 | |
EP4332242A1 (en) | Method for predicting prognosis of gastric cancer | |
KR20100086362A (ko) | 간암 진단 마커인 apoa1, 그를 포함하는 키트 | |
KR20150041375A (ko) | 신장독성 평가용 바이오마커 akr7a1 및 이를 이용한 신장독성 평가방법 | |
KR100777088B1 (ko) | 간암을 진단하기 위한 마커인 lcn2, midkine 및tfpi, 그를 포함하는 키트 및 상기 마커를 이용한 간암예측 방법 | |
AU2017254964A1 (en) | Urine markers for detection of bladder cancer | |
KR100814716B1 (ko) | 간암을 진단하기 위한 마커인 hla-dma, cd24 및sdfr1, 이들을 포함하는 키트 및 상기 마커를 이용한간암 예측 방법 | |
US20220064235A1 (en) | Urine Markers and Methods for Detection of Bladder Cancer and Treatment Thereof | |
KR20240054172A (ko) | 엑소좀 유래의 대장암 진단용 바이오 마커 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130530 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140609 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150701 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160614 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170629 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170802 Year of fee payment: 18 |